Marijuana Rescheduling Creates Legal Uncertainty in Trucking Drug Tests

Marijuana Rescheduling Creates a Structural Legal Crisis for DOT Drug Testing

On April 23, 2025, the DEA moved state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act, a seemingly technical regulatory action that threatens the legal foundation of mandatory drug testing for the entire trucking industry. While headlines focused on the rescheduling itself, the real impact lies in a structural vulnerability that supply chain leaders and fleet managers are only beginning to understand: the authority DOT uses to mandate marijuana testing may no longer be legally sound.

The problem is deceptively simple. DOT's testing authority flows through the Department of Health and Human Services, which issues the Mandatory Guidelines for Federal Workplace Drug Testing Programs. Those guidelines explicitly limit regulated employers to testing only for substances listed in Schedules I and II of the Controlled Substances Act. When state-licensed medical marijuana moved to Schedule III, HHS's statutory authority to include THC in the mandatory federal testing panel became legally questionable. The Omnibus Transportation Employee Testing Act of 1991, which gives DOT its testing mandate, requires DOT to follow HHS guidelines. If HHS cannot authorize Schedule III testing without new rulemaking, then DOT's current zero-tolerance framework—codified in 49 CFR Parts 40 and 382—sits on shaky legal ground.

The immediate operational answer is clear and unchanged: zero tolerance remains in effect. The Office of Drug and Alcohol Policy and Compliance (ODAPC) has not updated its guidance since December 19, 2025, before rescheduling occurred. Every fleet, every MRO, and every driver is bound by the same rules that governed them yesterday. A positive test still results in Clearinghouse placement. That number matters: approximately 60% of all positive tests in the FMCSA Clearinghouse stem from marijuana, affecting roughly 184,337 commercial drivers currently in prohibited status. For today's operations, nothing has changed.

But between the practical answer and the structural answer lies a chasm where real litigation risk lives. The distinction matters most for non-CDL commercial motor vehicle operators—a much larger and murkier population than CDL holders. Straight trucks under 26,001 pounds, cargo vans, pickup trucks towing trailers in certain configurations, and passenger vehicles used for-hire in some jurisdictions all qualify as commercial motor vehicles without triggering CDL requirements. These operators face varying, less uniformly codified testing requirements depending on their state, cargo type, and regulatory classification. For many of these drivers, the rescheduling creates genuine uncertainty about which standards even apply.

The Litigation Pathway Is Now Open

When the legal foundation for a regulation becomes questionable, litigation becomes easier to mount. Drivers in states with aggressive medical marijuana protections—California, Colorado, and similar jurisdictions—can now argue that their prescribed use of a federally recognized Schedule III controlled substance should not disqualify them from operating commercial equipment. That argument would lose in court today because Part 40 and Part 382 are still in effect. But it is structurally stronger after April 23 than it was before. State courts in medically protective jurisdictions may be more receptive to these challenges than federal courts, particularly where state law explicitly prohibits employment discrimination against medical marijuana patients.

The trucking industry received no comment period during this rulemaking despite direct implications for fleet hiring, driver retention, and operational compliance. The DEA used a treaty-obligations pathway under 21 U.S.C. 811(d)(1) to issue this as a final order without notice-and-comment procedures, specifically avoiding the procedural pathway that killed the Biden administration's prior rescheduling attempt. The Single Convention on Narcotic Drugs obligates the United States to schedule cannabis in a manner consistent with treaty commitments, and an OLC opinion from April 2024 concluded Schedule III satisfies those obligations. This is not casual policy-making; it is carefully engineered legal architecture designed to survive judicial challenge—which means the industry should assume this rescheduling is permanent.

What Supply Chain Leaders Should Do

The most likely resolution is eventual congressional or administrative action explicitly carving out marijuana testing for safety-sensitive transportation workers regardless of scheduling status. That carve-out does not exist yet. Until it does, supply chain teams should treat this as a permanent structural question requiring active monitoring and mitigation. Continue enforcing zero-tolerance policies with clear documentation, as current regulations remain controlling. Monitor ODAPC updates closely and consult legal counsel on state-specific medical marijuana employment protections, especially if your fleet operates in protective jurisdictions. Consider proactive compliance audits focusing on driver screening procedures and MRO protocols. Most critically, prepare for potential litigation by documenting the safety rationale for marijuana testing and the distinction between federal and state law in your policy frameworks.

The rescheduling does not change operations today, but it has fundamentally weakened the legal authority underlying those operations. Fleet managers who anticipate this structural vulnerability rather than react to future litigation will be better positioned to navigate what may be years of regulatory uncertainty.

Source: FreightWaves